_1547102581651.png?format=webp&height=120&width=120){kind=logo}
TFF Pharmaceuticals - About the company
TFF Pharmaceuticals is a public company based in Austin (United States), founded in 2018. It operates as a Developer of inhalation products for chronic respiratory diseases. TFF Pharmaceuticals has raised $22.2M in funding from Liquid Venture Partners. The company has 23 active competitors, including 10 funded and 5 that have exited. Its top competitors include companies like Theravance Biopharma, MediciNova and Expedition Therapeutics.
Company Details
Developer of inhalation products for chronic respiratory diseases. The company has proprietary technology,thin-film freezing to generate dry powder inhalers for various respiratory drugs. The technology is applicable for small molecules, biologics, and combinations.
- Website
- tffpharma.com
- Email ID
- *****@tffpharma.com
- Phone Number
- +1 **********
- Registered Address
- 1751 River Run, Suite 400 Fort Worth, Texas 76107
Key Metrics
Founded Year
2018
Location
Austin, United States
Stage
Public
Total Funding
$22.2M in 5 rounds
Latest Funding Round
Investors
Ranked
5th among 23 active competitors
Employee Count
15 as on Dec 31, 2022
Similar Companies
Exit Details
Public
Legal entities associated with TFF Pharmaceuticals
TFF Pharmaceuticals is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
TFF PHARMACEUTICALS, INC. CIN: 82-4344737 , United States, Active | Jan 23, 2018 | - | 15 (As on Dec 31, 2022) | - |
TFF Pharmaceuticals's IPO details
TFF Pharmaceuticals got listed on Oct 25, 2019.
Click here to take a look at TFF Pharmaceuticals's IPO in detail
Sign up to download TFF Pharmaceuticals' company profile
TFF Pharmaceuticals's funding and investors
TFF Pharmaceuticals has raised a total funding of $22.2M over 5 rounds. Its first funding round was on Apr 03, 2018. Its latest funding round was a Grant (prize money) round on Jul 03, 2023 for $*****. 1 investor participated in its latest round. TFF Pharmaceuticals has 4 institutional investors.
Here is the list of recent funding rounds of TFF Pharmaceuticals:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 03, 2023 | 4518233 | Grant (prize money) | 6099424 | 5124089 | 8643274 | 2375569 |
Jun 26, 2023 | 9569177 | Grant (prize money) | 1011487 | 3877070 | 8706737 | |
Aug 11, 2020 | 9713686 | Post IPO | 2795965 | 3612953 | 9413037 | 8621661 |
Access funding benchmarks and valuations. Sign up today!View details of TFF Pharmaceuticals's funding rounds and investors
TFF Pharmaceuticals' founders and board of directors
Founder? Claim ProfileTFF Pharmaceuticals' employee count trend
TFF Pharmaceuticals has 15 employees as of Dec 22. The total employee count is 275.0% more than what it was in Dec 21. Here is TFF Pharmaceuticals's employee count trend over the years:
Uncover TFF Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
TFF Pharmaceuticals's Competitors and alternates
Top competitors of TFF Pharmaceuticals include Theravance Biopharma, MediciNova and Expedition Therapeutics. Here is the list of Top 10 competitors of TFF Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Theravance Biopharma 2001, Francisco (United States), Public | Developer of therapeutics for inflammatory and immunological diseases | - | 68/100 | |
2nd | MediciNova 2000, San Diego (United States), Public | Developer of small molecule for the treatment of acute exacerbations of asthma and COPD | $83.9M | 60/100 | |
3rd | Expedition Therapeutics 2024, San Francisco (United States), Series B | Developer of treatments targeting inflammatory and respiratory diseases for patient care | $280M | 55/100 | |
4th |  Altesa Biosciences 2020, College Park (United States), Series B | Developer of drugs to treat RNA viruses | $110M | 54/100 | |
5th | _1547102581651.png?devicePixelRatio=2&height=30&width=30){kind=logo} TFF Pharmaceuticals 2018, Austin (United States), Public | Developer of inhalation products for chronic respiratory diseases | $22.2M | 51/100 | |
6th | ZEO ScientifiX 2011, Fort Lauderdale (United States), Seed | Biopharmaceutical company focused on researching novel biological therapeutics | $1M | - | 52/100 |
7th |  ReAlta Life Sciences 2018, Norfolk (United States), Series C | Developer of therapeutic drugs for acute inflammatory and rare diseases | $150M | 49/100 | |
8th |  Tessel Bio 2021, Cambridge (United States), Funding Raised | Pharmaceutical development firm harnessing the power of human physiology to discover new drugs | - | 38/100 | |
9th |  Elevation Pharmaceuticals 2007, San Diego (United States), Acquired | Developer of aerosol drug products for COPD patients | $77M | 36/100 | |
10th |  AeroRx 2023, La Jolla (United States), Series A | Developer of nebulized combination drug therapies for respiratory diseases | $21M | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on TFF Pharmaceuticals's competitors? Click here to see the top ones
TFF Pharmaceuticals's Investments and acquisitions
TFF Pharmaceuticals has made no investments or acquisitions yet.
Reports related to TFF Pharmaceuticals
Here is the latest report on TFF Pharmaceuticals's sector:
News related to TFF Pharmaceuticals
Filter this list•
•
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliveryGlobeNewswire•Sep 26, 2024•TFF Pharmaceuticals
•
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVIDGlobeNewswire•Sep 11, 2024•TFF Pharmaceuticals, Emory University, HHS
•
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal ImmunizationGlobeNewswire•Sep 10, 2024•TFF Pharmaceuticals
•
TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant RejectionGlobeNewswire•Aug 06, 2024•TFF Pharmaceuticals
•
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing OpportunitiesBioSpace•Jun 26, 2024•TFF Pharmaceuticals, Outcome Capital
•
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant RejectionBioSpace•Jun 24, 2024•TFF Pharmaceuticals
•
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical TestingGlobeNewswire•May 23, 2024•TFF Pharmaceuticals, Leidos
•
TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testingSeeking Alpha•May 20, 2024•Cleveland Clinic, TFF Pharmaceuticals
•
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant RejectionBioSpace•May 15, 2024•TFF Pharmaceuticals
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about TFF Pharmaceuticals
Explore our recently published companies
- Way - Helsinki based, 2024 founded, Seed company
- Delite - Hyderabad based, 2010 founded, Unfunded company
- Yuki - Tel Aviv based, 2023 founded, Seed company
- Hedgepointcapital.com - 2021 founded, Funding Raised company
- MicroRoboTech - Hangzhou based, 2025 founded, Series A company
- Semper Plugins - Durham based, 2011 founded, Acquired company
